it may be weakly associated with non-Hodgkin lymphoma. 3 HPgV is transmitted efficiently via intravenous and sexual routes, and the prevalence varies widely based on geographic location and the population studied. While male-to-male sex is an effective mode of transmission, HPgV is transmitted heterosexually and perinatally also. 4, 5 The prevalence of HPgV RNA ranges from 14% to 45% in HIV-positive persons. 6 Several groups have reported beneficial effects of HPgV viremia on HIV disease. [7] [8] [9] [10] [11] For example, Tillman et al reported longer AIDS-free survival, higher CD4 cell counts, and lower plasma HIV viral loads in individuals with HPgV RNA, as well as an inverse correlation between the HPgV and HIV viral loads. 9 Xiang et al further demonstrated prolonged survival among HIV-positive persons co-infected with HPg. 11 Bjorkman et al reported that clearance of HPgV replication during follow-up was associated with the poorest survival, 12 a finding that was confirmed in other studies. 10, 13 Nevertheless, prolonged survival in HPgV/HIV co-infected persons has not been reported by all studies. [12] [13] [14] [15] [16] Due to the potential importance of persistence of HPgV viremia, a meta-analysis 17 was conducted of prospective studies of HIV-positive persons with HPgV RNA. There was no conclusive evidence for an association between survival and HPgV infection early in HIV disease; however, there was a significant reduction in mortality when HPgV infection was present later in HIV disease. Clearance of HPgV viremia is associated with accelerated HIV disease compared to non-clearance. 3, 10, 12 At the population level, multiple HPgV genotypes exist, 18, 19 leading some to suggest that they impact HIV disease. 6, 20, 21 Muerhoff et al reported lower CD4 cell counts in HIV co-infected patients infected with HPgV 2a than in patients with subtype 2b. 21 We subsequently found that during HIV/HCV/ HPgV triple infection, Characterizing the mechanisms by which HPgV inhibits HIV replication may lead to novel therapeutic treatments for HIV disease.
Several potential pathways by which HPgV influences HIV replication and pathogenesis include altered chemokine expression, and downregulation of chemokine co-receptors. [26] [27] [28] Additionally, HPgV viremia is associated with stable T-helper 1 cytokine levels compared to HIV-infected individuals without HPgV in whom Th1 cytokines decreased and Th2 cytokines increased over time. 29 Numerous studies support the importance of the Th1/2 response to HIV infection. 30 However, a separate study found no significant differences in plasma CCL5, CXCL12/SDF-1, IL-7, or TNFα in the presence/absence of HPgV RNA. 31 More recent studies also suggest that HPgV activates the endogenous interferon system, thereby resulting in partial control of HIV replication. with an uncorrelated log-normal relaxed molecular clock, a generalized time reversible (GTR) model, and nucleotide site heterogeneity estimated using a gamma distribution. The BEAST MCMC analysis was run for a chain length of 200 000 000. All effective sample sizes were >100 indicating sufficient sampling. The maximum clade credibility tree was selected from the posterior tree distribution after a 10% burn-in using TreeAnnotator v1.7.5.
| Multiplex immunoassay
The current analysis included available serum samples chosen at random from 70 women co-infected with HIV and HPgV (study visits from April 1993 to January 1995), and 80 HIV-positive women who were HPgV RNA negative (study visits from April 1993 to October 1994) based on our previous study of HPgV in this cohort. 40 These 150 women did not differ at baseline from the remaining HIV-positive women in the HERS cohort with respect to race; however, they were older (median age 36.9 years vs 34.7 years; P < 0.001), had a higher median CD4 count (431.2 vs 367.6; P = 0.012), and lower log viral load (3.09 vs 3.20; P = 0.023). (minimal detectable concentration of 10 pg/mL).
| Statistical analysis
Wilcoxon rank-sum tests were utilized to compare baseline values for age, CD4 cell count, and HIV viral load for women included in the current analysis to the remaining HIV-positive women, whereas the chi-square test was used for the baseline comparison of race.
Categorical demographic and clinical factors were compared by HPgV RNA status (positive/negative) using either the chi-square test or
Fisher's exact test if any expected cell count was less than five. Age approximated a normal distribution and was compared by HPgV RNA status using the t-test. Cytokine/chemokine values (expressed in pg/ mL) were not normally distributed and were log-transformed prior to evaluation by HPgV RNA status and genotype (genotype 1/genotype 2) using separate Wilcoxon rank-sum tests. The value of undetectable cytokines/chemokines was set to half of the lowest detectable value for that cytokine/chemokine. In Figure 1 , the values at the bottom of each cytokine/chemokine denote the relative proportion of undetectable data. P values less than 0.05 were considered statistically significant for all tests, although P values less than 0.10 are also indicated Figures 1 and 2. 3 | RESULTS
| Characterization of patient population
We previously reported a 20.8% prevalence of HPgV RNA in the HERS cohort with most infections due to genotype 1 (44.3%) or genotype 2 (51.4%). 40 Patient demographics for the 150 women included in the current analysis are provided in Table 1 | 1907 values were significantly lower for HPgV positive compared to negative women for IL-4 (P < 0.001), IL-8 (P < 0.001), TGF-β 1 (P < 0.001), and IP-10 (P < 0.001). There were no significant differences between these two groups for IL-2, IL-10, MIP-1α, MIP-1β, or TNFα.
| Serum cytokine/chemokine expression by HPgV genotype
IFNγ values were higher for HPgV genotype 2 than for genotype 1 (P = 0.036). Although not statisitically signficant at P < 0.05, IL-10 
| DISCUSSION
Characterizing the mechanisms underlying the ability of HPgV to inhibit HIV replication may lead to novel therapeutic treatments for HIV disease.
In vitro infection of PBMCs with HPgV suggests that reduced HIV replication is related to the induction of chemokines and that this inhibitory effect can be reduced by antibodies to RANTES, MIP-1a, or MIP-1β. 28 The HPgV E2 glycoprotein also induces a dose-dependent release of RANTES and down regulation of CCR5 chemokine receptor expression, thereby blocking HIV entry. 27 Furthermore, the HPgV NS5A protein decreases CXCR4 receptor expression, upregulates the chemokine SDF-1, and inhibits HIV replication. 26 Similarly, we have reported that
HPgV alters CCR5 and CXCR4 surface expression on CD4 + T cells. (73.3%) were male, and there were no significant differences in cytokine/chemokine levels in persons with or without HPgV. 35 Divergent results among these studies and ours may reflect the distinct at-risk populations studied. Moreover, the sample size, cross-sectional study design, and unique population characteristics may limit comparability to other published studies. Additionally, the exact dates of HIV and/or HPgV infection are unknown, although this information is rarely known, particularly for HPgV, which is not evaluated in most routine clinical settings. The present study was considered exploratory in nature; therefore, the Bonferroni correction for multiple comparisons was not applied.
Nonetheless, application of this correction would have changed the significance for only chemokine-IFNγ-from significant to nonsignificant for both HPgV status and genotype comparisons.
Our study focused on HPgV in women given that viral infections are frequently understudied in females and the potential for genderspecific differences in cytokine expression reviewed in reference. 
